New antibody infusion AM-928 enters early human trials for Hard-to-Treat cancers
NCT ID NCT05687682
First seen May 02, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This early-phase study tests a new drug called AM-928, given as an IV infusion, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 38 participants will receive different doses to see how the body handles the drug and whether it shows any signs of shrinking tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, 10002, Taiwan
Conditions
Explore the condition pages connected to this study.